Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Blood (2024) 144 (Supplement 1): 73.

https://doi.org/10.1182/blood-2024-205557

Published: 2024

Journal Articles

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Alessandra Trojani, Alessandro Beghini, Luca Emanuele Emanuele Bossi, Marta Rachele Stefanucci, Cassandra Palumbo, Antonino Greco, Annamaria Frustaci, Barbara Di Camillo, Marco Montillo, Roberto Cairoli

Blood (2023) 142 (Supplement 1): 3406.

https://doi.org/10.1182/blood-2023-180580

Published: 2023

Journal Articles

Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods

Luca Emanuele Emanuele Bossi, Cassandra Palumbo, Alessandra Trojani, Agostina Melluso, Barbara Di Camillo, Alessandro Beghini, Marco Montillo, Roberto Cairoli

Blood (2023) 142 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2023-185825

Published: 2023

Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood (2022) 140 (8): 839–850.

https://doi.org/10.1182/blood.2021015014

Published: 2022

Includes: Supplemental data

Journal Articles

Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance ( IgM MGUS ) Compared to Healthy Subjects

Alessandra Trojani, Barbara Di Camillo, Luca Emanuele Bossi, Antonino Greco, Livia Leuzzi, Alessandra Tedeschi, Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Agostina Melluso, Alessia Panzeri, Marco Montillo, Alessandro Beghini, Roberto Cairoli

Blood (2021) 138 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2021-147712

Published: 2021

Journal Articles

Genetic Landscape and Clonal Evolution Patterns of CEBPA -Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis

Livia Leuzzi, Valentina Mancini, Silvio Marco Veronese, Laura Pezzetti, Valentina Motta, Michele Nichelatti, Rosa Greco, Giambattista Bertani, Marco Montillo, Alessandro Beghini, Roberto Cairoli

Blood (2021) 138 (Supplement 1): 2363.

https://doi.org/10.1182/blood-2021-149248

Published: 2021

Journal Articles

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider, Lone Bredo Pedersen, Renee C. Tschumper, Lesley-Ann Sutton, Panagiotis Baliakas, Lydia Scarfò, Ellen J. van Gastel, Marine Armand, Eugen Tausch, Bella Biderman, Constance Baer, Davide Bagnara, Alba Navarro, Anne Langlois de Septenville, Valentina Guido, Gerlinde Mitterbauer-Hohendanner, Aleksandar Dimovski, Christian Brieghel, Sarah Lawless, Manja Meggendorfer, Kamila Brazdilova, Matthias Ritgen, Monica Facco, Cristina Tresoldi, Andrea Visentin, Andrea Patriarca, Mark Catherwood, Lisa Bonello, Andrey Sudarikov, Katrina Vanura, Maria Roumelioti, Hana Skuhrova Francova, Theodoros Moysiadis, Silvio Veronese, Krzysztof Giannopoulos, Larry Mansouri, Teodora Karan-Djurasevic, Raphael Sandaltzopoulos, Csaba Bödör, Franco Fais, Arnon Kater, Irina Panovska, Davide Rossi, Salem Alshemmari, Panagiotis Panagiotidis, Paul Costeas, Blanca Espinet, Darko Antic, Letizia Foroni, Marco Montillo, Livio Trentin, Niki Stavroyianni, Gianluca Gaidano, Paola Francia di Celle, Carsten Niemann, Elias Campo, Achilles Anagnostopoulos, Christiane Pott, Kirsten Fischer, Michael Hallek, David Oscier, Stephan Stilgenbauer, Claudia Haferlach, Diane Jelinek, Nicholas Chiorazzi, Sarka Pospisilova, Marie-Paule Lefranc, Sofia Kossida, Anton W. Langerak, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos

Blood (2021) 137 (10): 1365–1376.

https://doi.org/10.1182/blood.2020007039

Published: 2021

Includes: Supplemental data

Journal Articles

Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137202

Published: 2020

Journal Articles

Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-137024

Published: 2020

Journal Articles

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Gian Matteo Rigolin, Annamaria Frustaci, Alfonso Piciocchi, MS, Andrea Visentin, MDPhD, Orsola Vitagliano, Marta Coscia, MD PhD, Lucia Farina, Gianluca Gaidano, Roberta Murru, MD, Marzia Varettoni, Luca Arcaini, Francesca Cibien, MD, Rossella Paolini, Paolo Sportoletti, MD, Daniela Pietrasanta, MD, Anna Lia Molinari, MD, Francesca M. Quaglia, Luca Laurenti, MD, Roberto Marasca, MD, Monia Marchetti, MD, Annalisa Chiarenza, MD PhD, Francesca Romana Mauro, MD PhD, Omar Perbellini, Donato Mannina, MD, Rosaria Sancetta, MD, Attilio Olivieri, MD, Stefano Molica, MD, Fabrizio Pane, MD, Caterina Patti, MD, Fiorella Iliariucci, Alessandro Gozzetti, Catello Califano, MD, Piero Galieni, Accursio Fabio Augello, MD, Daniele Vallisa, MD, Francesca Cura, Enrico Crea, Paola Fazi, MD, Giulia Zamprogna, MD, Mauro Krampera, MD PhD, Livio Trentin, MD, Felicetto Ferrara, MD, Massimo Gentile, Marco Montillo, Robin Foà, MD, Antonio Cuneo, MD

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-134669

Published: 2020

Journal Articles

Cell Surface Proteins of B Cells and Plasmacells Are Differently Expressed in Waldenström's Macroglobulinemia (WM) Patients Vs. Subjects with Monoclonal Gammopathy of Uncertain Significance (IgMMGUS) Vs. Healthy Donors

Alessandra Trojani, PhD, Barbara Di Camillo, Luca Emanuele Bossi, Alessandra Tedeschi, MD, Annamaria Frustaci, Alessandro Beghini, Marco Montillo, Roberto Cairoli, MD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-134569

Published: 2020

Journal Articles

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Rosemary Anne Harrup, Carolyn Owen, MDFRCPC, James D'Rozario, Tadeusz Robak, MDPhD, Arnon P. Kater, Marco Montillo, Javier de la Serna, Marek Trněný, MD, Su Young Kim, Edward Bataillard, Marcus Lefebure, Michelle Boyer, John F. Seymour

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137415

Published: 2020

Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136109

Published: 2020

Journal Articles

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Blood (2019) 134 (Supplement_1): 1754.

https://doi.org/10.1182/blood-2019-128388

Published: 2019

Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 355.

https://doi.org/10.1182/blood-2019-123930

Published: 2019

Journal Articles

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Alessandra Trojani, Alessandra Tedeschi, MD, Annamaria Maria Frustaci, Marina Deodato, Luca Emanuele Bossi, Barbara Di Camillo, Marco Montillo, MD, Enrica Morra, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5036.

https://doi.org/10.1182/blood-2019-125577

Published: 2019

Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Blood (2019) 133 (19): 2031–2042.

https://doi.org/10.1182/blood-2018-08-870238

Published: 2019

Includes: Supplemental data

Journal Articles

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Blood (2018) 132 (23): 2446–2455.

https://doi.org/10.1182/blood-2018-05-850461

Published: 2018

Includes: Supplemental data

Journal Articles

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Matthew S. Davids, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, James Essell, MD, Nicole Lamanna, MD, Zsolt Nagy, MD PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Stephan Stilgenbauer, Paolo Ghia, MD PhD, Julio Delgado, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Ulrich Jaeger, MD

Blood (2018) 132 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2018-99-117521

Published: 2018

Journal Articles

Health-Related Quality of Life in Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undeterminated Significance (IgM-MGUS)

Anna Maria Frustaci, Michele Nichelatti, PhD, Marina Deodato, MD, Maddalena Mazzucchelli, MD, Marco Montillo, MD, Roberto Cairoli, Alessandra Tedeschi, MD

Blood (2018) 132 (Supplement 1): 3593.

https://doi.org/10.1182/blood-2018-99-111444

Published: 2018

NARROW

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance ( IgM MGUS ) Compared to Healthy Subjects

Genetic Landscape and Clonal Evolution Patterns of CEBPA -Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax

Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Cell Surface Proteins of B Cells and Plasmacells Are Differently Expressed in Waldenström's Macroglobulinemia (WM) Patients Vs. Subjects with Monoclonal Gammopathy of Uncertain Significance (IgMMGUS) Vs. Healthy Donors

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Health-Related Quality of Life in Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undeterminated Significance (IgM-MGUS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only